Challenges in the post genomic era for the development of tests for leprosy diagnosis.
Leprosy diagnosis is based mainly on clinical manifestations and no laboratory test is available to diagnose asymptomatic disease or to predict disease progression among exposed individuals. Novel comparative genomic in silico analyses and molecular biology tools have discovered unique Mycobacterium leprae proteins with potential diagnostic application. Tuberculoid paucibacillary leprosy (PB) shows low antibodies titers and strong Th1 type/ IFN-gamma specific cell mediated immunity (CMI), while lepromatous multibacillary patients (MB) show high antibody titers and low CMI. Therefore, laboratory tests for PB and MB leprosy diagnosis will require CMI and antibody based assays. Serologically reactive recombinant Mycobacterium leprae proteins were identified and may be used in conjunction with PGL-I to improve MB patient diagnosis. Mycobacterium leprae recombinant proteins and synthetic peptides have been tested for CMI-interferon gamma based assays for PB diagnosis. Modified PGL-I serology incorporating new Mycobacterium leprae antigens and CMI tests based on IFN-gamma gamma production may permit the detection of leprosy PB and MB forms in endemic countries.
Stefani
Mariane Martins de Araújo
MM
Tropical Pathology and Public Health Institute, Federal University of Goiás, GO, Brazil. mstefani@iptsp.ufg.br
D000942:Antigens, Bacterial; D006017:Glycolipids; D006801:Humans; D007111:Immunity, Cellular / Q000276:immunology; D007371:Interferon-gamma / Q000276:immunology; D015440:Leprosy, Lepromatous / Q000175:diagnosis* / Q000276:immunology; D015441:Leprosy, Tuberculoid / Q000175:diagnosis* / Q000276:immunology; D009166:Mycobacterium leprae / Q000235:genetics* / Q000276:immunology; D016133:Polymerase Chain Reaction; D018417:Th1 Cells / Q000276:immunology
D000942:Antigens, Bacterial; D006017:Glycolipids; C045169:phenolic glycolipid I, Mycobacterium leprae; D007371:Interferon-gamma